← Kelly Casteel, MD

From 7+3 to Targeted Therapy

An interactive, clinician-facing chronicle of the trials that rebuilt AML care — from four decades of the “7+3” cytarabine–anthracycline backbone through hypomethylating agents, the 2017 explosion of FLT3 and IDH inhibitors, venetoclax, and the mutation-directed menin inhibitor era. Click any drug to trace its Phase 1→3→approval lineage; click a trial for arms, endpoints, results, and FDA/EMA milestones.

Data verified against ClinicalTrials.gov & primary literature · last reviewed Jul 2026

View

Drug class

Trial phase

Ph 1 Ph 2 Ph 3

Status

Approved Investigational Withdrawn / failed

Activity

Ongoing only

NCCN

In NCCN v3.2026 Category 1 only

Reference

Solid outline = approved Dashed outline = investigational Dashed rose = withdrawn / failed Pulsing dot = ongoing trial ✓badge = FDA / EMA approved NCCN category badge (1 / 2A / biomarker) Ambient curve = rising survival as approvals accrue

Scroll horizontally → · click a drug node to open its trial lineage

NCCN regimens by clinical setting

Derived from NCCN Clinical Practice Guidelines in Oncology — Acute Myeloid Leukemia, Version 3.2026

Preference tiers (Preferred / Other Recommended / Useful in certain circumstances) and Categories of Evidence (1, 2A, 2B) are summarised for reference and attributed to NCCN. This is not a reproduction of the guideline; consult the authoritative, current version at nccn.org. Click a drug chip to jump to that agent’s trial lineage. Mutation-restricted (FLT3 / IDH1/2 / NPM1 / KMT2A) options are noted inline.